Kintegral Advisory LLC Cuts Position in Stryker Co. (NYSE:SYK)

by · The Cerbat Gem

Kintegral Advisory LLC trimmed its position in shares of Stryker Co. (NYSE:SYK – Free Report) by 4.4% during the 4th quarter, Holdings Channel reports. The fund owned 3,065 shares of the medical technology company’s stock after selling 142 shares during the period. Kintegral Advisory LLC’s holdings in Stryker were worth $1,106,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Dividend Assets Capital LLC raised its stake in Stryker by 4.0% during the fourth quarter. Dividend Assets Capital LLC now owns 29,093 shares of the medical technology company’s stock valued at $10,475,000 after purchasing an additional 1,124 shares in the last quarter. Transcend Capital Advisors LLC increased its holdings in shares of Stryker by 11.5% in the 4th quarter. Transcend Capital Advisors LLC now owns 10,942 shares of the medical technology company’s stock worth $3,940,000 after buying an additional 1,132 shares during the last quarter. Bradley Foster & Sargent Inc. CT raised its position in shares of Stryker by 2.9% during the 4th quarter. Bradley Foster & Sargent Inc. CT now owns 60,329 shares of the medical technology company’s stock valued at $21,721,000 after buying an additional 1,679 shares in the last quarter. Paradigm Asset Management Co. LLC purchased a new stake in shares of Stryker during the 4th quarter valued at about $1,188,000. Finally, Cassaday & Co Wealth Management LLC bought a new position in shares of Stryker in the 4th quarter valued at about $982,000. 77.09% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on SYK. Truist Financial boosted their price objective on Stryker from $409.00 to $413.00 and gave the stock a “hold” rating in a research note on Thursday, January 30th. StockNews.com downgraded Stryker from a “buy” rating to a “hold” rating in a research report on Thursday, January 30th. Morgan Stanley upgraded Stryker from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $370.00 to $445.00 in a research report on Monday, December 2nd. JMP Securities reiterated a “market perform” rating on shares of Stryker in a research report on Tuesday, February 18th. Finally, Robert W. Baird raised their target price on shares of Stryker from $378.00 to $405.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. Five research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, Stryker presently has a consensus rating of “Moderate Buy” and an average target price of $422.15.

View Our Latest Report on Stryker

Insider Buying and Selling

In related news, Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the sale, the director now owns 14,895 shares of the company’s stock, valued at $5,705,827.65. The trade was a 14.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Ronda E. Stryker sold 201,392 shares of the stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the transaction, the director now owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is owned by company insiders.

Stryker Trading Down 1.0 %

Shares of NYSE SYK opened at $382.59 on Friday. Stryker Co. has a twelve month low of $314.93 and a twelve month high of $406.19. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. The business has a fifty day simple moving average of $378.07 and a two-hundred day simple moving average of $368.99. The firm has a market cap of $145.99 billion, a PE ratio of 49.30, a price-to-earnings-growth ratio of 2.93 and a beta of 0.96.

Stryker (NYSE:SYK – Get Free Report) last released its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period last year, the firm earned $3.46 earnings per share. Analysts expect that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a $0.84 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 annualized dividend and a yield of 0.88%. Stryker’s dividend payout ratio (DPR) is 43.30%.

Stryker Profile

(Free Report)

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

Featured Articles

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK – Free Report).